NCT02544932 is a Phase 3 clinical trial of dabigatran in Atrial Fibrillation, sponsored by Kyunghee University Medical Center.

Who is sponsoring NCT02544932?

NCT02544932 is sponsored by Kyunghee University Medical Center.

What drugs are being tested in NCT02544932?

Interventions in NCT02544932: dabigatran, ribaroxaban, Warfarin.

What condition does NCT02544932 study?

NCT02544932 studies Atrial Fibrillation.

Is NCT02544932 still recruiting?

NCT02544932 is currently status unknown. Last updated 7 September 2015.

Last reviewed 2015-09-07 · How we verify

NCT02544932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Randomized Study for Evaluating Vascular Protective Effects of New Oral Anticoagulants in High Risk Patients With Atrial Fibrillation

Status unknown Phase 3 Last updated 7 September 2015

What this trial tests

Phase 3 trial testing dabigatran in Atrial Fibrillation in 55 participants. Status unknown.

Timeline

1 October 2015

Primary endpoint
1 September 2017

1 September 2017

Quick facts

Lead sponsor	Kyunghee University Medical Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	1 October 2015
Primary completion	1 September 2017
Estimated completion	1 September 2017
Sites	1 location across South Korea

Drugs / interventions tested

dabigatran (DABIGATRAN) — full drug profile →
ribaroxaban — full drug profile →
Warfarin (warfarin) — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Kyunghee University Medical Center

Who can join

Adults 40 to 85, any sex, with Atrial Fibrillation. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The changes in reactive hyperemia index (RHI)
Time frame: 12months

Sponsor's own description

Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure.
Premer C, Kanelidis AJ, Hare JM, Schulman IH. · · 2019 · cited 78× · PMID 30899903 · DOI 10.1016/j.mayocpiqo.2018.12.006
Endothelial Dysfunction in Heart Failure: What Is Its Role?
Drera A, Rodella L, Brangi E, Riccardi M, et al · · 2024 · cited 28× · PMID 38731063 · DOI 10.3390/jcm13092534
Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial.
Kim JB, Joung HJ, Lee JM, Woo JS, et al · · 2016 · cited 9× · PMID 27558002 · DOI 10.1186/s13063-016-1541-8

Verify or expand the search:

Other trials of dabigatran

Trials testing the same drug.

NCT05838664 — A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) · completed
NCT04808934 — NOAC Portuguese Real World Study · withdrawn
NCT03536611 — Dabigatran Versus Warfarin With NVAF Who Undergo PCI · Phase 4 · unknown
NCT03254147 — Medical Need of OAC Reversal · completed
NCT03441633 — Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) · completed

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Kyunghee University Medical Center trials

Trials by the same sponsor.

NCT06183697 — Multi-omics Database Construction of Healthy Korean Volunteers · recruiting
NCT06113497 — A Prospective Study on the Comparison of Postoperative Pain According to the Use of Cocktail Therapy in Laminoplasty · Phase 4 · unknown
NCT06049914 — Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care · NA · unknown
NCT03515070 — Microbiome and Genetic Analysis of Familial IBD · completed
NCT03589183 — Gut Microbiome in Inflammatory Bowel Disease · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02544932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyunghee University Medical Center
Last refreshed: 7 September 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02544932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing